Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
We report the use of anti-interleukin-5 (mepolizumab) during an 18-month period in a pediatric hypereosinophilic syndrome. Infusions every 3 months allowed better control of hypereosinophilic syndrome flares and maintained blood eosinopenia with significantly less steroid use compared with all other therapies (prednisolone alone, interferon alpha, or imatinib mesylate).
Mehr
Sam
S
Department of Allergy & Immunology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia.
Rego
Sylvan
S
Kakakios
Alyson
A
Kilham
Henry
H
Kemp
Andrew
A
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D002648:Child; D004804:Eosinophils / Q000166:cytology; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy*; D000068877:Imatinib Mesylate; D007262:Infusions, Intravenous; D015848:Interleukin-5 / Q000037:antagonists & inhibitors / Q000276:immunology*; D007958:Leukocyte Count; D008297:Male; D010879:Piperazines / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; D015848:Interleukin-5; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; C434107:mepolizumab; D011239:Prednisolone